Research programme: HIV infection therapies - Merck

Drug Profile

Research programme: HIV infection therapies - Merck

Alternative Names: IDX-12989; IDX989; NV-05; NV-05A

Latest Information Update: 25 Sep 2014

Price : $50

At a glance

  • Originator Idenix Pharmaceuticals
  • Developer Merck & Co
  • Class Pyrroles; Sulfones
  • Mechanism of Action HIV integrase inhibitors; RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 14 Mar 2007 Data presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI-2007) added to the adverse events, pharmacokinetcs and Viral Infections antimicrobial activity section
  • 10 Nov 2006 Idenix Pharmaceuticals has filed an IND with the US FDA for the treatment of HIV infections
  • 18 Aug 2006 Idenix intends to file an IND with the FDA in the US for two non-nucleoside reverse transcritase inhibitors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top